In Alzheimer’s mice, memory restored with cancer drug

Posted on

Star–like glial cells in red surround alpha beta plaques in the cortex of a mouse with a model of Alzheimer’s Disease. The drug, AZD05030, developed by Astra Zeneca proved disappointing in treating solid tumors but appears to block damage triggered during the formation of amyloid-beta plaques, a hallmark of Alzheimer’s disease. The new study, funded by an innovative National Institutes of Health (NIH) program to test failed drugs on different diseases, has led to the launch of human trials to test the efficacy of AZD05030 in Alzheimer’s patients. “With this treatment, cells under bombardment by beta amyloid plaques show restored synaptic connections and reduced inflammation, and the animal’s memory, which was lost during the course of the disease, comes back,” said Stephen M. Strittmatter, the Vincent Coates Professor of Neurology and senior author of the study. In the last five years, scientists have developed a more complete understanding of the complex chain of events that leads to Alzheimer’s disease.

The new drug blocks one of those molecular steps, activation of the enzyme FYN, which leads to the loss of synaptic connections between brain cells. Several other steps in the disease process have the potential to be targets for new drugs, Strittmatter said. “The speed with which this compound moved to human trials validates our New Therapeutic Uses program model and serves our mission to deliver more treatments to more patients more quickly,” said Christopher P. Austin, M.D., director of NIH’s National Center for Advancing Translational Sciences (NCATS), which funded the work.

http://www.sciencedaily.com/  Science Daily

http://www.sciencedaily.com/releases/2015/03/150331145138.htm  Original web page at Science Daily

Tags: ,

Sidebar